SS-31 (Szeto-Schiller 31), also known as
MTP-131 or Elamipretide, is a small, cell-permeable tetrapeptide
(D-Arg-dimethylTyr-Lys-Phe-NH2) that is one of the Szeto-Schiller (SS)
peptides. It selectively targets the inner mitochondrial membrane and binds selectively
to cardiolipin. Elamipretide is a pharmacological agent whose effects on
mitochondria can improve physiological parameters in mitochondrial myopathies
and aging.
Clinical studies show that treatment with
SS-31 reverses the age-related decline in maximum mitochondrial ATP production
(ATPmax) and oxidative phosphorylation coupling (P/O), restores redox
homeostasis, improves mitochondrial quality, and increases exercise tolerance
without increasing mitochondrial content.
Elamipretide has been studied for the
treatment of numerous conditions, including heart failure, macular
degeneration, accelerated wound healing, and hypertension. The drug’s potential
is considered quite high. SS-31 is currently approved for the treatment of
Barth syndrome, dry age-related macular degeneration, primary mitochondrial
myopathy, and Leber hereditary optic neuropathy.
AREAS OF
APPLICATION
SS-31 can accumulate in mitochondria and
neutralize reactive oxygen species. The drug has pronounced antioxidant and
anti-inflammatory properties. It protects mitochondria—the cellular energy
plants—from damage. SS-31 stabilizes the inner mitochondrial membrane, improves
ATP production, reduces oxidative stress and inflammation, thereby restoring
cellular function, improving endurance, protecting the heart and brain, and
slowing aging.
The drug is used in various aspects of
rehabilitation and anti-aging therapy.
Cardiology:
protecting the heart during ischemia and improving myocardial function.
Neurology: supporting
neurons. SS-31 is potentially beneficial for Alzheimer’s and Parkinson’s
diseases.
Metabolism: improves
cellular function in diabetes and obesity.
Rehabilitation and sports medicine: increases endurance and accelerates recovery.
DOSAGE
The lyophilized form of SS-31 is intended for
subcutaneous administration. The recommended initial dosage for preventive
therapy courses is 1-2 mg per day, and for intensive recovery courses, 4-10 mg
per day, depending on the patient’s condition and the specific therapy. To
achieve a synergistic effect, SS-31 can be used in combination with MOTS-C,
BPC-157, and other peptides. Consult your physician for individualized dosage,
administration regimen, and drug compatibility.
